FindTrial
Sign In

Efficacy of supplementation with an omega-6/omega-3 ratio of 4/1 and signaling in autism spectrum disorders

The effects of supplementation with an omega-6/omega-3 ratio of 4/1 and related fatty acids derived signaling in autism spectrum disorders - Efficacy of supplementation with a higher ratio of omega-6/omega-3 in autism spectrum disorders

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT1091220162
Enrollment
50
Registered
2014-02-10
Start date
2012-08-25
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

autism spectrum disorders

Interventions

Intervention type:DRUG Name of intervention:fatty acid supplementation Dose form / Japanese Medical Device Nomenclature:CAPSULE Route of administration / Site of application:GASTROENTERAL Dose per adm

Sponsors

None
Lead Sponsor
Professor George Imataka, Department of Pediatrics Dokkyo Medical University, Japan Associate Profesot Youhei Kawasaki,Department of Drug Evaluation and Informatics, School of Clinical Research Center, University of Shizuoka. Japan.
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Individuals who met DSM-IV criteria of autism with physicaly health

Exclusion criteria

Exclusion criteria: Individuals who have medical or mental illness except for developmental disorders. Individuals who have usually deviated fat consumption.

Design outcomes

Primary

MeasureTime frame
Aberrant Behavior Checklist—

Secondary

MeasureTime frame
Social Responsiveness Scale—

Countries

Japan

Contacts

Public ContactKunio Yui

Fujita Health UniversityUniversity

yui16@bell.ocn.ne.jp+81-54-264-5591

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026